Fate Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDFate Therapeutics, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 75), indicating performance broadly in line with the market. Earnings growth of 39% provides fundamental context to the price action. However, with RSI at 85, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $1.45 | +57.66% | ABOVE |
| 50 SMA | $1.33 | +72.10% | ABOVE |
| 100 SMA | $1.24 | +84.80% | ABOVE |
| 150 SMA | $1.24 | +84.54% | ABOVE |
| 200 SMA | $1.20 | +91.38% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is FATE in an uptrend right now?
FATE has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is FATE overbought or oversold?
FATE's RSI (14) is 85. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is FATE outperforming the market?
FATE has a Relative Strength (RS) Rating of 75 out of 99. FATE is performing about average compared to the market.
Where is FATE in its 52-week range?
FATE is trading at $2.29, which is 95% of its 52-week high ($2.41) and 92% above its 52-week low ($0.91).
How volatile is FATE?
FATE has a Beta of 2.17 and 52-week volatility of 90%. It's more volatile than the S&P 500 - expect bigger swings.